'Unprecedented' Survival of 15 Months Seen in CLEOPATRA'Unprecedented' Survival of 15 Months Seen in CLEOPATRA

Pertuzumab plus trastuzumab adds a 15-month survival benefit in HER2-positive metastatic breast cancer. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news